Black men twice as likely to die from prostate cancer compared to white men
the ONA take:
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men, according to an English population study published in BMC Medicine.
Additionally, Asian men are half as likely to be diagnosed, or die from, prostate cancer in their lifetime compared to white men.
Researchers led by Alison Cooper of Prostate Cancer UK and Public Health England studied prostate cancer incidence and mortality data in England from 2008 to 2010 from a variety of sources, including Public Health England and the Office for National Statistics. In total, their sample size included 25,635,649 men, with 102,252 prostate cancer diagnoses and 26,521 deaths as a result of prostate cancer.
They found that lifetime risk of being diagnosed with prostate cancer in England was about 1 in 8 (13.3 percent) for white men, 1 in 4 (29.3 percent) for black men, and 1 in 13 (7.9 percent) for Asian men.
Risk of dying from prostate cancer in England was found to be about 1 in 24 (4.2 percent) in white men, 1 in 12 (8.7 percent) in black men, and 1 in 44 (2.3 percent) in Asian men.
Independent of ethnicity, white, black and Asian men with prostate cancer diagnosis were found to have a one third chance of dying from the disease.
Further work is needed to understand the mechanisms for the higher risk found in black men.
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|